Nanjing Tung Chit Pharmaceutical

Nanjing Tung Chit Pharmaceutical is a Chinese pharmaceutical company and a subsidiary of Simcere Pharmaceutical Group. The company is primarily recognized for its production of nedaplatin, a second-generation platinum-based chemotherapy agent marketed under the brand name Jiebaishu. Acquired by Simcere in 2007, Nanjing Tung Chit focuses on the manufacturing of oncology treatments and branded generic pharmaceuticals. It operates as part of Simcere's broader manufacturing infrastructure in Nanjing, contributing to the group's portfolio of high-incidence disease treatments. The company maintains GMP-compliant facilities for the production of injectable and solid oral dosage forms. Its operations are integrated into Simcere's research, development, and commercialization network across China.